Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

Cellular "barcoding" in mice unravels the origins of blood

The origins of our blood may not be quite what we thought. Using cellular "barcoding" in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children's Hospital led the study, published in Nature on June 15.

15 Jun 2022

SARS-CoV-2 recombinant isolated from chronic COVID-19 patient

A new research paper in the journal Viruses reports the isolation of a recombinant strain in a patient infected with the virus for over a year.

13 Jun 2022

Treatment with immunity-boosting protein enhances the function of CAR-T cells in fighting blood cancers

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers.

13 Jun 2022

Creating CAR T cells without an immune brake

T cells are usually very good at eliminating diseased cells. But they seem to fail when it comes to tumor cells.

10 Jun 2022

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

A protein that the body naturally produces could become an important new immunotherapy drug in the cache of cancer-fighting tools available to oncologists.

9 Jun 2022

Childhood cancer survivors 80% more likely to be undertreated for cardiovascular risk factors

Adults who survive childhood cancer have a higher risk of cardiovascular disease than the general population, yet they are 80% more likely to be undertreated for several cardiovascular risk factors: hypertension (also called high blood pressure), diabetes and high cholesterol, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

8 Jun 2022

COVID-19 vaccination may offer less effective and shorter-lasting protection for some cancer patients

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalization and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

7 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

New study uncovers the impact of genetic mutations on lifelong blood cell production

New research has uncovered how genetic mutations hijack the production of blood cells in different periods of life.

1 Jun 2022

New research may open a window to treating aggressive form of B-cell acute lymphoblastic leukemia

Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic leukemia with rearrangements of the mixed lineage leukemia gene, or MLL B-ALL.

1 Jun 2022

Risk factors for COVID-19 in patients with hematological malignancies

Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.

26 May 2022

New initiative aims to increase collaboration and accelerate high-impact cancer immunotherapy

The accelerated advancement of cancer immunology and immunotherapy, a type of biological therapy that boosts the immune system's ability to recognize and kill cancer cells, has significantly improved the effectiveness of cancer treatment and patient outcomes.

25 May 2022

Study brings precision medicine closer to reality for diffuse large B cell lymphoma

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets.

25 May 2022

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

24 May 2022

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.

23 May 2022

Medicaid expansion associated with increase in survival rates among patients newly diagnosed with cancer

A new large study led by researchers at the American Cancer Society (ACS) shows Medicaid expansion under the Affordable Care Act (ACA) was associated with an increase in two-year overall survival rates among patients newly diagnosed with cancer, especially among non-Hispanic Black people and people living in rural areas.

18 May 2022

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.

13 May 2022

UC Davis researchers identify a protein that keeps Kaposi's sarcoma-associated herpesvirus dormant

A team of UC Davis researchers has identified a protein in the cancer cell's nucleus as a critical agent keeping Kaposi's sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body's immune system.

11 May 2022

Discovery provides critical clues to why many immunotherapies trigger dangerous side effects

It's not often that a failed clinical trial leads to a scientific breakthrough. When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.

5 May 2022